Biotech: Page
-
Getty Images
Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise
Senda Biosciences decided to raise a $123 million Series C round rather than test public markets with an initial offering, its top executive said.
By Gwendolyn Wu • Aug. 16, 2022 -
NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
State of Play‘Treg’ cell therapy: bringing CAR-T to autoimmune disease
At least seven companies, including five richly funded startups, are developing cell-based treatments for inflammatory conditions, making it one of biotech’s most competitive fields.
By Ben Fidler • Aug. 16, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Jacob Bell/BioPharma Dive
Despite failed trial, Brainstorm asks FDA to approve ALS drug
The move comes less than a month after the agency agreed to review Biogen’s tofersen — another ALS drug with a questionable record in clinical testing.
By Jacob Bell • Updated Aug. 18, 2022 -
Gabriel Kuchta via Getty Images
UK approves Moderna’s two-pronged COVID-19 booster
Britain’s drug regulator is the first public health authority to clear a vaccine designed to fight omicron as well as the original strain of the virus.
By Jonathan Gardner • Aug. 15, 2022 -
Permission granted by Seagen
Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology
An arbitrator ruled against Seagen in a dispute over technology used in Enhertu and other Daiichi Sankyo drugs, stopping an attempt by Seagen to collect lucrative royalties.
By Ben Fidler • Aug. 12, 2022 -
Getty Images
Shifting focus, ProQR to seek partners for stalled eye drugs
The company will wind down five trials involving two drug candidates and lay off more staff, prioritizing instead its RNA-editing technology.
By Delilah Alvarado • Aug. 11, 2022 -
Kena Betancur via Getty Images
A biotech startup gives Merck its next shot at treating Alzheimer’s
Boston-based Cerevance is searching for new drug targets for neurological diseases like Alzheimer’s, although CEO Craig Thompson wouldn’t reveal what its work with Merck will take aim at.
By Gwendolyn Wu • Aug. 9, 2022 -
Permission granted by Upstream Bio
Q&ASamantha Truex on biotech hiring, competing for funding and Upstream’s next steps
The CEO recently led Upstream through a $200 million financing that will support development of an inflammatory disease drug. “We have what investors probably want at this time,” she told BioPharma Dive.
By Ned Pagliarulo • Aug. 9, 2022 -
Elizabeth Regan/BioPharma Dive
Karuna shares soar on schizophrenia drug results
The company plans to ask regulators to approve its KarXT therapy based on the results, which one analyst called “as good as one could hope for.”
By Jacob Bell • Aug. 8, 2022 -
Sarah Silbiger via Getty Images
Acadia turned back by FDA on second attempt to get psychosis drug approved
The agency issued Acadia a complete response letter for pimavanserin, for which the company had sought to win an expanded clearance in Alzheimer’s disease psychosis.
By Ned Pagliarulo • Aug. 5, 2022 -
Permission granted by Michael Goderre / Boston Children’s Hospital
ElevateBio, Boston Children’s launch startup to test new approach to ‘off-the-shelf’ cell therapy
Spun out of a Boston Children’s research lab, the biotech is the first to emerge from a partnership ElevateBio and the hospital struck to create new cell and gene therapy companies.
By Delilah Alvarado • Aug. 4, 2022 -
Gilead, following cell therapy approval, impresses Wall Street with fast sales
Together, the biotech’s two CAR-T therapies earned $368 million between April and June, a substantial jump over last year and above what analysts forecast.
By Jacob Bell • Aug. 3, 2022 -
Getty Images
Alnylam drug succeeds in key heart disease study, boosting company
The success of Alnylam's treatment in a trial known as APOLLO-B could pave the way for the biotech to reach consistent profitability, should the FDA sign off on an approval application.
By Ben Fidler • Aug. 3, 2022 -
Courtesy of IDRx
IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations
Founded by entrepreneur Alexis Borisy, the company comes equipped with two experimental medicines it licensed from Merck KGaA and Blueprint Medicines.
By Ned Pagliarulo • Aug. 2, 2022 -
Courtesy of Strand Therapeutics
Q&AStrand CEO on founder-led biotech, venture capital and the market’s retreat
Jake Becraft, founder and current chief of mRNA startup Strand Therapeutics, argues biotech would be healthier if more scientists and researchers lead the companies they start.
By Ned Pagliarulo • Aug. 2, 2022 -
Photography courtesy of Nasdaq, Inc.
How Belite Bio, a small, under-the-radar drugmaker, emerged as one of biotech’s best performing IPOs
Belite's shares have risen nearly 500% from their IPO price at a time when many other newly public biotech companies are struggling to hold their value.
By Delilah Alvarado • Updated Aug. 2, 2022 -
Nuvation to cut workforce by 35% as it scraps lead drug program
The company, which is led by former Medivation executives and focuses on cancer research, said the shake-up is in response to an “internal risk-benefit analysis” that raised doubts about its most advanced program.
By Jacob Bell • Aug. 1, 2022 -
Sarah Silbiger via Getty Images
Concert to seek approval for hair loss drug after second study success
The biotech plans to file an application with the FDA in the first half of next year for clearance in alopecia areata, potentially positioning it to compete with Eli Lilly and Pfizer for market share.
By Ned Pagliarulo • Aug. 1, 2022 -
Courtesy of Sarepta
Sarepta to ask FDA for accelerated approval of Duchenne gene therapy
After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.
By Jonathan Gardner • July 29, 2022 -
Alnylam reveals longer wait for anticipated drug trial results
Important data from the APOLLO study of the biotech's drug Onpattro are due before the end of August, Alnylam said Thursday.
By Ned Pagliarulo • July 28, 2022 -
Courtesy of Vicinitas Therapeutics
Novartis-linked startup launches with technology designed to remove ‘destroy’ tags on helpful proteins
Vicinitas and its protein-stabilizing research have attracted $65 million from a group of investors that includes a16z, Deerfield and GV.
By Jacob Bell • July 28, 2022 -
Courtesy of AbCellera
Versant partners with AbCellera to arm startups with better antibodies
The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO.
By Ned Pagliarulo • July 27, 2022 -
Elizabeth Regan/BioPharma Dive
BridgeBio advances drug for dwarfism after study data
The highest tested dose of BridgeBio’s drug helped the bones of children with achondroplasia grow faster, leading the company to expand study enrollment.
By Ned Pagliarulo • July 26, 2022 -
Permission granted by Seagen
Seagen, Astellas claim positive results in study key to cancer drug's success
The mid-stage trial tested the companies’ drug Padcev with Merck’s Keytruda in first-line bladder cancer. The data are reportedly a factor in Merck’s talks with Seagen over a potential buyout.
By Ned Pagliarulo • July 26, 2022 -
Permission granted by Biogen
FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug
Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators.
By Jacob Bell • July 26, 2022
Previous
